LMU Clinical Pharmacology
@KlinPharm
Division of Clinical Pharmacology, LMU University Hospital
Metabolites as agents and targets for cancer immunotherapy nature.com/articles/s4157… This new Review discusses the role of metabolic pathways in cancer and immune cells in shaping the tumour microenvironment, and how they can be targeted to improve anticancer immune responses
A heartfelt thank you from KlinPharm to Prof. Stefan Endres for a lifetime of leadership 🥂@LMU_Muenchen @Harvard_Imm
Two new doctors on the loose! Huge congratulations to Emanuele Carlini and Jan Gärtig 🥂#PhD
Great collaborative effort 🥂@i_piseddu #Anzlab @EnricoNDeToni @KBoettcherLab @JuliaMayerle
Great to see our new study on a vulnerable phase in HCC immunotherapy highlighted. Thank you @Erman_Akkus, and thanks to all collaborators!
Can't be stopped 🏃⚡️- team #KlinPharm at the B2Run in Munich's Olympiapark #B2Run2025
Big congrats to Kathrin Gabriel #Koboldlab on her paper "Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy" - out now 💥 nature.com/articles/s4139…
Now online! Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagement dlvr.it/TLfrWv
Great team work ⚡️⚡️#Anzlab @BeroutiMarleen @hornung_lab @CarellThomas @CellCellPress
🥳Amazing publication from the @hornung_lab, in collab. with the @CarellThomas lab, on the innate immune system: how modified RNA tricks the immune system. Big shout-out to the two first authors, @BeroutiMarleen and Mirko Wagner! sciencedirect.com/science/articl… lmu.de/en/newsroom/ne…
Very excited to share our review on "Metabolites as agents and targets for cancer immunotherapy" in @NatRevDrugDisc! read it here: rdcu.be/etAMD @SpringerNature @KlinPharm
Inspired by @OliveiraMann, @BekereIndra, and Veronika Merold’s article in @MolecularCell, my latest cover art illustrates OAS2’s unique requirement for Golgi membrane localization, essential for restricting viruses! @TU_Muenchen #sciart ⌬ #research ⌬ #chemistry
I’m very excited to share our first preprint “Structural Basis for OAS2 Regulation and its Antiviral Function” from my postdoc together with Veronika Merold (Vroni) from NTase lab with @OliveiraMann biorxiv.org/content/10.110…
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis jitc.bmj.com/content/13/6/e…
📢Call for Reading: *Role and Potential of Different #T Helper #Cell Subsets in Adoptive Cell Therapy* 🙌Citations: 28 👨🔬by David Andreu-Sanz and Sebastian Kobold #OpenAccess 🔓mdpi.com/2072-6694/15/6…
🗞️🗞️🗞️König and Schnurr Lab in @MolecularCell @LM_Koenig @OliveiraMann @BekereIndra, Veronika Merold and @PichlmairL Structural basis for OAS2 regulation and its antiviral function cell.com/molecular-cell…
Structural basis for OAS2 regulation and its antiviral function dlvr.it/TLBmgD
#KlinPharm in good cheer🍻Celebrating a new #Koboldlab paper out soon in @jitcancer
Celebrating our medical students📚#FöFoLe @LMU_Muenchen
CD86 is a promising immunotherapeutic target in cHL, and the CD86–CTLA-4 axis orchestrates an immunosuppressive cHL tumor microenvironment. ow.ly/uXQY50VugVk #lymphoidneoplasia #immunobiologyandimmunotherapy
I’m grateful for the opportunity to present my research at the #ITOC11 conference. Many thanks to Vivien Menkhoff and Anja Hauptstein who substantially contributed to the presented research, to my mentors for their support, and to the organizers for the interesting programme!
Prof. Sebastian Kobold presents #WashUMed’s Robert D. Schreiber with the #ITOC11 Lifetime Achievement Award💐💐@washumedicine @CIR_AACR
ITOC 11 Lifetime Achievement Award presented to Robert D. Schreiber, St. Louis, MO, United States